KR20120107121A - 면역원성 조성물 - Google Patents

면역원성 조성물 Download PDF

Info

Publication number
KR20120107121A
KR20120107121A KR1020127019061A KR20127019061A KR20120107121A KR 20120107121 A KR20120107121 A KR 20120107121A KR 1020127019061 A KR1020127019061 A KR 1020127019061A KR 20127019061 A KR20127019061 A KR 20127019061A KR 20120107121 A KR20120107121 A KR 20120107121A
Authority
KR
South Korea
Prior art keywords
composition
polypeptide
immunogenic
pcpa
phtd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020127019061A
Other languages
English (en)
Korean (ko)
Inventor
스콧 갈리샹
케빈 하퍼
벨마 르쥬틱
마르티나 오취스 오취스
게리 모어필드
페르난도 아우사르
마리-대니엘 살라
Original Assignee
사노피 파스퇴르 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 파스퇴르 리미티드 filed Critical 사노피 파스퇴르 리미티드
Publication of KR20120107121A publication Critical patent/KR20120107121A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127019061A 2009-12-22 2010-12-20 면역원성 조성물 Abandoned KR20120107121A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US61/289,236 2009-12-22
US32566010P 2010-04-19 2010-04-19
US61/325,660 2010-04-19

Publications (1)

Publication Number Publication Date
KR20120107121A true KR20120107121A (ko) 2012-09-28

Family

ID=44194860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127019061A Abandoned KR20120107121A (ko) 2009-12-22 2010-12-20 면역원성 조성물

Country Status (12)

Country Link
US (1) US20130183350A1 (cg-RX-API-DMAC7.html)
EP (1) EP2515938A4 (cg-RX-API-DMAC7.html)
JP (2) JP5894083B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120107121A (cg-RX-API-DMAC7.html)
CN (1) CN102802664B (cg-RX-API-DMAC7.html)
AR (1) AR079712A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010335970B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018343A2 (cg-RX-API-DMAC7.html)
CA (1) CA2783955A1 (cg-RX-API-DMAC7.html)
IL (2) IL220576B (cg-RX-API-DMAC7.html)
WO (1) WO2011075823A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204628B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150142788A (ko) * 2014-06-11 2015-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939105B (zh) 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
JP6236086B2 (ja) * 2012-10-17 2017-11-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
AU2015228542A1 (en) * 2014-03-10 2016-09-22 Sanofi Pasteur Limited Immunogenic compositions
SG11201706081SA (en) * 2015-01-27 2017-08-30 3M Innovative Properties Co Alum-containing coating formulations for microneedle vaccine patches
GB2556002B (en) * 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
EP4395818A4 (en) * 2021-09-02 2025-08-20 Vaxcyte Inc STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2178A1 (fr) * 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
KR101916787B1 (ko) * 2005-03-23 2019-01-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP2010501012A (ja) * 2006-08-17 2010-01-14 ザ ユーエービー リサーチ ファウンデーション 免疫原性ＰｃｐＡポリペプチドおよびその使用
WO2009012588A1 (en) 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
AU2009208299B2 (en) * 2008-02-01 2015-01-22 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
CA2748149C (en) * 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150142788A (ko) * 2014-06-11 2015-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물

Also Published As

Publication number Publication date
US20130183350A1 (en) 2013-07-18
CN102802664A (zh) 2012-11-28
CN102802664B (zh) 2017-04-05
JP2016104776A (ja) 2016-06-09
IL220576B (en) 2018-03-29
AR079712A1 (es) 2012-02-15
EP2515938A1 (en) 2012-10-31
ZA201204628B (en) 2013-02-27
JP2013515015A (ja) 2013-05-02
AU2010335970A1 (en) 2012-07-05
CA2783955A1 (en) 2011-06-30
BR112012018343A2 (pt) 2017-06-27
AU2010335970B2 (en) 2016-11-03
IL242592A (en) 2017-10-31
JP5894083B2 (ja) 2016-03-23
WO2011075823A1 (en) 2011-06-30
EP2515938A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
KR20120107121A (ko) 면역원성 조성물
AU2019246878B2 (en) Compositions relating to a mutant Clostridium difficile toxin and methods thereof
KR101741426B1 (ko) 변형된 스트렙토코커스 뉴모니아 뉴몰리신(ｐｌｙ) 폴리펩타이드
AU2012207089B2 (en) Vaccines and compositions against Streptococcus pneumoniae
CN102939105B (zh) 免疫原性组合物和相关的方法
CN106103469B (zh) 突变型葡萄球菌抗原
US9944680B2 (en) Composition for immunization against Streptococcus pneumoniae
EP3634981B1 (en) Lipidated streptococcus pneumoniae
EP2498812A1 (en) Immunizing composition for reducing streptococcal infections
US20170157233A1 (en) Immunogenic Compositions
HK40047921A (en) Mutant staphylococcal antigens
AU2016254447A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151218

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170307

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170307

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170627

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170607

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151218

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171013

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20180426

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180213

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170926

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170627

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170607

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151218

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee